19-Gene Panel for Ulcerative Colitis Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating ulcerative colitis (UC) are limited by the complex pathogenesis involving genetic, microbial, and environmental factors, with unclear roles of tumor necrosis factor-alpha (TNFα) and a lack of effective gene markers for predicting treatment responsiveness.
Innovation Solution
Identification of specific gene panels, comprising 19 or 5 genes, with modified expression levels that serve as biomarkers predictive of treatment responsiveness in UC patients, using microarray technology and nucleic acid-based methods for diagnostic and prognostic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microarray technology is used to analyze gene expression profiles, then the ability to identify treatment-responsive patients is improved, but the complexity of the diagnostic method increases
Solution Approach 1:
The patent segments the complex gene expression analysis into a focused 19-gene panel, isolating only the most relevant genes for predicting infliximab response. This segmentation maintains measurement precision while reducing the complexity burden of analyzing thousands of genes simultaneously.
Solution Approach 2:
The patent extracts and isolates the critical 19 genes from the complete gene expression profile obtained through microarray technology. By taking out only the essential predictive genes, the method preserves prediction accuracy while simplifying the diagnostic approach for clinical implementation.
2Reliability
If a 19-gene panel is used for prediction, then the reliability of treatment response assessment is improved, but the cost and complexity of testing increase
Solution Approach 1:
The patent performs preliminary identification of the 19 critical genes through comprehensive microarray analysis and validation studies before implementing the final diagnostic test. This preliminary action ensures high prediction reliability while allowing the final test to use a simplified, validated gene panel that reduces testing complexity.
Solution Approach 2:
The patent changes the parameter scope from analyzing thousands of genes to focusing on a specific 19-gene panel with validated predictive value. This parameter change maintains prediction reliability by concentrating on the most informative genes while reducing testing complexity through a manageable gene set.
3Adaptability or versatility
If comprehensive microarray analysis is performed, then novel gene markers can be discovered, but the time and resources required for analysis increase
Solution Approach 1:
The patent performs comprehensive microarray analysis and gene discovery as a preliminary research phase to identify the 19-gene predictive panel. Once the panel is established and validated, routine clinical testing can proceed efficiently with the predefined gene set, significantly reducing analysis time while preserving the ability to discover novel markers in future research.
Solution Approach 2:
The patent applies partial action by performing comprehensive microarray analysis only during the initial discovery phase, then transitioning to focused analysis of the validated 19-gene panel for routine applications. This approach balances the need for gene discovery capability with the practical constraint of analysis time and resources.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the prediction of treatment suitability and identification of UC patients likely to respond to therapy, allowing for personalized treatment approaches and improved management of the disease.
Implementation Method 1
Microarray technology is a powerful tool since it enables analysis of the expression of thousands of genes simultaneously
Data Source
AI summary
A method for assessment of the suitability of a target therapy for a gastrointestinal-related disorder, such as ulcerative colitis, in a subject evaluates the presence, absence, and/or magnitude of expression of one or more genes in a 19- or 5-member gene panel in a sample. The method enables identification of the effectiveness of target therapies prior to starting a patient on such therapies.